{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:59:16Z","timestamp":1753891156833,"version":"3.41.2"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>T-SPOT.TB<jats:sup>\u00ae<\/jats:sup>, one of the screening tests for latent tuberculosis infection (LTBI), yields invalid results in human T-cell leukemia virus type 1 (HTLV-1)-positive patients with rheumatoid arthritis. However, the detailed mechanisms behind this invalidation are unclear. Additionally, it remains unclear whether T-SPOT.TB<jats:sup>\u00ae<\/jats:sup> or QuantiFERON-TB (QFT) is more useful in HTLV-1-positive patients with rheumatic disease (RD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Among all of the HTLV-1-positive RD patients who visited our department between August 2012 and December 2022, 44 patients who were screened using T-SPOT.TB\u00ae were included in the analysis. QFT testing was performed in 33 of the 44 patients, and the results were compared with that of T-SPOT.TB\u00ae. Furthermore, we performed a culture experiment mimicking T-SPOT.TB\u00ae using peripheral blood mononuclear cells (PBMCs) obtained from HTLV-1-positive patients with RD. Additionally, T-cell subsets with autonomous product IFN-\u03b3 were analyzed using a flow cytometer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the included patients, 13 (29.5%) were invalid for T-SPOT.TB\u00ae because of the increased number of negative control spots. The median HTLV-1 proviral load in the invalid group was higher than that in the valid group (2.45 vs. 0.49 copies\/100 PBMCs, respectively, <jats:italic>p<\/jats:italic> = 0.002). QFT was performed in all 33 patients, including 13 patients who were invalid in T-SPOT.TB\u00ae. The main source of IFN-\u03b3 production was CD8+ T-cells in the T-SPOT.TB\u00ae mimic experiment. Furthermore, Tax-expressing CD4+ T-cells and Tax-specific cytotoxic CD8+ T-cells were more frequently observed in patients with invalid results than in patients with valid results. CD4+ T-cell depletion in the T-SPOT.TB\u00ae mimic experiment reduced the population of IFN-\u03b3 producing CD8+ T cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>T-SPOT.TB\u00ae may be invalidated by the interaction between Tax-expressing CD4+ T-cells and cytotoxic CD8+ T-cells. Moreover, HTLV-1-associated immune reactions due to contact between these cells may be unlikely to occur in QFT using whole blood. Therefore, our results reveal the superiority of QFT over T-SPOT.TB\u00ae as a screening test for LTBI in HTLV-1-positive patients with RD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1480506","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T04:40:32Z","timestamp":1730176832000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Antiviral immune response against HTLV-1 invalidates T-SPOT.TB\u00ae results in patients with HTLV-1-positive rheumatic diseases"],"prefix":"10.3389","volume":"15","author":[{"given":"Masatoshi","family":"Kimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiko","family":"Umekita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Iwao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsumi","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Hashikura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yayoi","family":"Hashiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Hidaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Sugata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yorifumi","family":"Satou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiga","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140101","article-title":"Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: international recommendations","volume":"91","author":"Iannone","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2012.00322","article-title":"Adult T-cell leukemia: a review of epidemiological evidence","volume":"3","author":"Iwanaga","year":"2012","journal-title":"Front Microbiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28606","article-title":"Lower prevalence of anti-HTLV-1 as expected by previous models among first-time blood donors in Japan","volume":"95","author":"Sagara","year":"2023","journal-title":"J Med Virol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30252-3","article-title":"Incidence of human T-lymphotropic virus 1 infection in adolescent and adult blood donors in Japan: a nationwide retrospective cohort analysis","volume":"16","author":"Satake","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(07)70081-6","article-title":"Human T-lymphotropic virus 1: recent knowledge about an ancient infection","volume":"7","author":"Gonz\u00e1lez","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/943867","article-title":"Opportunistic infections in patients with HTLV-1 infection","volume":"2015","author":"Tanaka","year":"2015","journal-title":"Case Rep Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30402-5","article-title":"Association between HTLV-1 infection and adverse health outcomes: a systematic review and meta-analysis of epidemiological studies","volume":"20","author":"McGregor","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3201\/eid2603.190571","article-title":"Clinical characteristics of disseminated strongyloidiasis, Japan, 1975-2017","volume":"26","author":"Narita","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.1006-22","article-title":"Factors influencing the indeterminate results in a T-SPOT. TB test: a matched case-control study","volume":"62","author":"Herai","year":"2023","journal-title":"Intern Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0233159","article-title":"Human T-cell leukemia virus type 1 may invalidate T-SPOT. TB assay results in rheumatoid arthritis patients: a retrospective case-control observational study","volume":"15","author":"Umekita","year":"2020","journal-title":"PloS One"},{"key":"B11","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1080\/14397595.2018.1519890","article-title":"The time-sequential changes of risk factors for adult T-cell leukemia factors for adult T-cell leukemia development in human T-cell leukemia virus-positive patients with rheumatoid arthritis: a retrospective cohort study","volume":"29","author":"Umekita","year":"2019","journal-title":"Mod Rheumatol"},{"unstructured":"T-SPOT. TB package insert PI-TB-US-0001","key":"B12"},{"unstructured":"QuantiFERON\u00ae-TB Gold plus (QFT\u00ae-Plus) package insert","key":"B13"},{"key":"B14","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/cas.2015.106.issue-5","article-title":"Advanced human T-cell leukemia virus type 1 carriers and early-stage indolent adult T-cell leukemia-lymphoma are indistinguishable based on CADM1 positivity in flow cytometry","volume":"106","author":"Kobayashi","year":"2015","journal-title":"Cancer Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1086\/jid.2005.191.issue-7","article-title":"The clonal expansion of human T lymphotropic virus type 1-infected T cells: a comparison between seroconverters and long-term carriers","volume":"191","author":"Tanaka","year":"2005","journal-title":"J Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3169","article-title":"CADM1 expression and stepwise downregulation of CD7 are closely associated with clonal expansion of HTLV-I-infected cells in adult T-cell leukemia\/lymphoma","volume":"20","author":"Kobayashi","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1620\/tjem.157.1","article-title":"Monoclonal antibody defining tax protein of human T-cell leukemia virus type-I","volume":"157","author":"Lee","year":"1989","journal-title":"Tohoku J Exp Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2017.12.005","article-title":"Utility of the T-SPOT\u00ae. TB test\u2019s borderline category to increase test resolution for results around the cut-off point","volume":"108","author":"Rego","year":"2018","journal-title":"Tuberculosis (Edinb)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/apl.2016.19.issue-1","article-title":"Evaluation of interferon-gamma release assay (T-SPOT.TB(\u2122)) for diagnosis of tuberculosis infection in rheumatic disease patients","volume":"19","author":"Jiang","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.cca.2018.09.012","article-title":"Prevalence and influencing factors of the high nil-control spot count in T-SPOT.TB: a matched case-control study","volume":"487","author":"Sun","year":"2018","journal-title":"Clin Chim Acta"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00117207","article-title":"Indeterminate test results of T-SPOT.TB performed under routine field conditions","volume":"31","author":"Beffa","year":"2008","journal-title":"Eur Respir J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2710282","article-title":"Performance of LTBI screening in patients with rheumatic diseases using two different interferon-gamma releasing assays","volume":"27","author":"Zhang","year":"2022","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.16.0038","article-title":"Comparative utility of interferon-\u03b3 release assay, QuantiFERON\u00ae TB-GIT and T-SPOT\u00ae.TB in rheumatoid arthritis","volume":"20","author":"Matsumura","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/v15020468","article-title":"HAS-flow may be an adequate method for evaluating human T-cell leukemia virus Type 1 infected cells in human T-cell leukemia virus type 1-positive rheumatoid arthritis patients receiving antirheumatic therapies: A retrospective cross-sectional observation study","volume":"15","author":"Umekita","year":"2023","journal-title":"Viruses"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006517","article-title":"Abnormally high levels of virus-infected IFN-gamma+ CCR4+ CD4+ CD25+ T cells in a retrovirus-associated neuroinflammatory disorder","volume":"4","author":"Yamano","year":"2009","journal-title":"PloS One"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/v10120691","article-title":"Cytokine networks dysregulation during HTLV-1 infection and associated diseases","volume":"10","author":"Futsch","year":"2018","journal-title":"Viruses"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v98.3.721","article-title":"High production of interferon gamma but not interleukin-2 by human T-lymphotropic virus type I-infected peripheral blood mononuclear cells","volume":"98","author":"Hanon","year":"2001","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1089\/AID.2018.0290","article-title":"Interferon-\u03b3 secretion enzyme-linked immunospot assay determined among human T cell lymphotropic virus type 1-infected subjects: a potential laboratory marker for early HTLV-1-associated myelopathy\/tropical spastic paraparesis diagnosis","volume":"36","author":"Apoliano","year":"2020","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.161.1.482","article-title":"Demonstration of human T lymphotropic virus type I (HTLV-I) tax-specific CD8+ lymphocytes directly in peripheral blood of HTLV-I-associated myelopathy\/tropical spastic paraparesis patients by intracellular cytokine detection","volume":"161","author":"Kubota","year":"1998","journal-title":"J Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI75250","article-title":"HTLV-1 induces a Th1-like state in CD4+CCR4+ T cells","volume":"124","author":"Araya","year":"2014","journal-title":"J Clin Invest"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-011-0937-1","article-title":"Molecular mechanisms of HTLV-1 infection and pathogenesis","volume":"94","author":"Yasunaga","year":"2011","journal-title":"Int J Hematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.4.1386.004k22_1386_1392","article-title":"Abundant tax protein expression in CD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes","volume":"95","author":"Hanon","year":"2000","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/348245a0","article-title":"Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease","volume":"348","author":"Jacobson","year":"1990","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/3.8.761","article-title":"Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV-I-infected cells","volume":"3","author":"Kannagi","year":"1991","journal-title":"Int Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1089\/088922201300343735","article-title":"HLA-a*26, HLA-b*4002, HLA-b*4006, and HLA-b*4801 alleles predispose to adult T cell leukemia: the limited recognition of HTLV type 1 tax peptide anchor motifs and epitopes to generate anti-HTLV type 1 tax CD8(+) cytotoxic T lymphocytes","volume":"17","author":"Yashiki","year":"2001","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/NEN.0000000000000141","article-title":"Visualization of HTLV-1-specific cytotoxic T lymphocytes in the spinal cords of patients with HTLV-1-associated myelopathy\/tropical spastic paraparesis","volume":"74","author":"Matsuura","year":"2015","journal-title":"J Neuropathol Exp Neurol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-9-46","article-title":"HTLV-1 modulates the frequency and phenotype of FoxP3+CD4+ T cells in virus-infected individuals","volume":"9","author":"Satou","year":"2012","journal-title":"Retrovirology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001117","article-title":"HLA class I binding of HBZ determines outcome in HTLV-1 infection","volume":"6","author":"Macnamara","year":"2010","journal-title":"PloS Pathog"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1480506\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T04:40:35Z","timestamp":1730176835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1480506\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2024.1480506"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1480506","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2024,10,29]]},"article-number":"1480506"}}